Abstract:The cannabinoid type 2 receptor (CB2R), a G protein-coupled receptor (GPCR), is an important regulator of immune cell function and a promising target for to treat chronic inflammation and fibrosis. While CB2R is typically targeted by small organic molecules, including endo-, phyto- and synthetic cannabinoids, peptides may offer a different interaction space, owing to their larger size and greater contact area they facilitate differential interactions with a specific receptor target. Here we explore plant-derived cyclic cystine-knot peptides as ligands of the CB2R. Cyclotides are known for their exceptional biochemical stability. Recently they gained attention as modulators of GPCR signaling and as templates for designing peptide ligands with improved pharmacokinetic properties over linear peptides. Cyclotide-based ligands for CB2R were profiled based on a peptide-enriched extract library comprising nine plant species. Employing pharmacology-guided fractionation and peptidomics we identified cyclotide vodo-C1 from sweet violet plant (Viola odorata) as a full agonist of CB2R with an affinity (Ki) of 1 µM and a potency (EC50) of 8 µM. Leveraging deep learning networks we verified the structural topology of vodo-C1 and modelled its molecular volume in comparison to the CB2R ligand binding pocket. In a fragment-based approach we designed and characterized vodo-C1-based bicyclic peptides (vBCL1-4), aiming to reduce size and improve potency. Opposite to vodo-C1, the vBCL peptides lacked the ability to activate the receptor, but acted as negative allosteric modulators or neutral antagonists of CB2R. This study introduces a new macrocyclic peptide phytocannabinoid, which served as template for the development of synthetic CB2R peptide modulators. These findings offer opportunities for future peptide-based probe and drug development at cannabinoid receptors.

Oral activity of a nature-derived cyclic peptide for the treatment of multiple sclerosis

Plant-based production of an orally active cyclotide for the treatment of multiple sclerosis

Design and screening of a glial cell-specific, cell penetrating peptide for therapeutic applications in multiple sclerosis

Development and Challenges of Cyclic Peptides for Immunomodulation

An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease

Potential Application of Plant-Derived Compounds in Multiple Sclerosis Management

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Immunomodulatory Therapies of Multiple Sclerosis

Cyclic peptide therapeutics: past, present and future

Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis

Phenotypic Screening-based Identification of 3,4-Disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis.

Discovery and development of macrocyclic peptide modulators of the cannabinoid 2 receptor

Natural compounds as potential therapeutic candidates for multiple sclerosis: Emerging preclinical evidence

The Role of Glucagon-Like Peptide-1 Agonists in the Treatment of Multiple Sclerosis: A Narrative Review

Therapeutic Potential of a Novel Glucagon-like Peptide-1 Receptor Agonist, NLY01, in Experimental Autoimmune Encephalomyelitis

Inflammation-Targeted Biomimetic Nano-Decoys via Inhibiting the Infiltration of Immune Cells and Effectively Delivering Glucocorticoids for Enhanced Multiple Sclerosis Treatment

Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase Γ (pi3kγ) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)

Unlocking Novel Therapies: Cyclic Peptide Design for Amyloidogenic Targets through Synergies of Experiments, Simulations, and Machine Learning

Combined in vivo effect of N -acylethanolamine-hydrolyzing acid amidase and glycogen synthase kinase-3β inhibition to treat multiple sclerosis

Cyclic Peptides in Pipeline: What Future for These Great Molecules?

Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction